www.thestreet.com

www.thestreet.com
Share

www.thestreet.com

 •  October 17

MARIETTA, Ga., Oct. 17, 2017 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading biopharmaceutical company developing and marketing regenerative and therapeutic biologics utilizing human placental tissue allografts with patent-protected processes for multiple sectors of healthcare, announced today that the Company has been notified by...

www.thestreet.com

 •  October 15

Jim Cramer says Allergan (AGN - Get Report) is "the cheapest big-capitalization drug stock in the universe," so he'll buy more shares of the lackluster drugmaker for his charitable trust if the price drops below $200. "Allergan just been an out-and-out disappointment, [so] why hold it? Ennui? Lack of discipline?" Cramer asked during an exclusive...

www.thestreet.com

 •  October 12

NEW YORK, Oct. 12, 2017 /PRNewswire/ -- Male Health Drug Development Pipeline Review, 2017 Summary Male hypogonadism is characterized by androgen deficiency and infertility. Hypogonadism can be caused by disorders at the hypothalamic or pituitary level (hypogonadotropic forms) or by testicular dysfunction (hypergonadotropic forms). There are a...

www.thestreet.com

 •  February 22

Pfizer (PFE) , the world's biggest drugmaker, said Wednesday that it's abandoning its European listings due to liquidity issues. "Following a determination by the company that there is a limited trading or liquidity of its common stock on the Main Market of the London Stock Exchange," Pfizer said. The pharmaceutical giant also said it has applied...

www.thestreet.com

 •  February 14

BEIJING (TheStreet) -- The thrill is back for Chinese pharmaceutical companies and their investors because Pfizer (PFE) is about to lose its China patent rights for the erectile dysfunction drug Viagra. The U.S. drug giant's exclusive rights to sell the active ingredient sildenafil citrate under the trade name Viagra expires in China in July....

www.thestreet.com

 •  February 14

BEIJING (TheStreet) -- Long lines of patients snaking through China's overcrowded hospitals offer living proof of the huge potential for health care companies on the mainland. Much of that potential could be realized over the next few years as consumers grow wealthier and the government eases market controls, according to analysts who follow...